China patents its first indigenously developed COVID vaccine by CanSino

China patents first indigenously developed COVID vaccine by CanSino - We The World Magazine
Image courtesy of cottonbro via Pexels

Chinese authorities have approved patent applications for the first indigenously developed vaccine for novel coronavirus by biotechnology firm called CanSino Biologics Inc and the Academy of Military Medical Sciences.

The Chinese vaccine prototype is a recombinant adenovirus vaccine named Ad5-nCoV which has been jointly developed by Chinese military infectious disease expert Chen Wei and biopharmaceutical firm CanSino Biologics Inc. state-affiliated media Global Times reports.

In a statement sent to the media on Sunday, CanSino affirmed that the patent approval reflects the Chinese intellectual progress in terms of vaccine development and confirms the vaccine’s safety and efficacy.

The application for the patent was submitted at mid-March and was approved on August 11, the patent statement said. As per Chinese State-backed media, the nation’s patent approval is subjected to very high standards of uniqueness and innovation both nationally and internationally.

What is this vaccine?

The vaccine essentially injects a weakened common cold virus in the human body that has the genetic material of the novel coronavirus, with the sole purpose to train the immune system to make antibodies against the COVID-19 spike proteins and fight with it.

Few vaccines presently in progress and some in advanced stages of development, including the ones by the UK and Russia are vaccines based on adenovirus.

A recent randomized, double-blind, placebo-controlled, phase 2 trial (details published in the journal The Lancet), which was funded by CanSino to test the efficacy and safety of ‘recombinant adenovirus vaccine’ found the intramuscular jab “induced significant immune responses in the majority of recipients after a single immunization.”

The Lancet study also found older people have a lesser immune response to the virus, compared to younger people and they might need an additional dose of the vaccine for an equal response in tandem with the young recipients, People’s Daily reported.

More, larger phase studies are pending to test the longevity of the vaccine and effectiveness of the doses.